Preoperative serum vascular endothelial growth factor-A is a marker for subsequent recurrence in colorectal cancer patients

Diseases of the Colon and Rectum

Volumn 52, Issue 5, 2009, Pages 993-999

  Alabi, Andrew A ^a   Suppiah, Aravind ^a   Madden, Leigh A ^a   Monson, John R ^b   Greenman, John ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Colorectal cancer; Local recurrence; Survival; Vascular endothelial growth factor A

Indexed keywords

ANTINEOPLASTIC AGENT; VASCULOTROPIN A; TUMOR MARKER; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; COHORT ANALYSIS; COLON ADENOCARCINOMA; COLORECTAL CARCINOMA; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LONG TERM CARE; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; MUCINOUS CARCINOMA; MULTIMODALITY CANCER THERAPY; PREDICTION; PREOPERATIVE EVALUATION; PROGNOSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RECURRENT CANCER; ADENOCARCINOMA; BLOOD; COLORECTAL TUMOR; LYMPH NODE METASTASIS; MORTALITY; PREOPERATIVE CARE; REGRESSION ANALYSIS; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM RECURRENCE, LOCAL; PREOPERATIVE CARE; PROGNOSIS; REGRESSION ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67651183805     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/DCR.0b013e31819ed3bc     Document Type: Article

References (39)

1. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet 2005;365:153-165
2. Skibber JM, Minsky BD, Hoff PM. Cancers of the gastrointestinal tract. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:1230-1238
3. Benson AB, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004;22:2918-2926 (Pubitemid 41079912)
4. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748-753 (Pubitemid 30179746)
5. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes'B colorectal cancer patients: how much evidence is enough? Ann Oncol 2003;14:1026-1028
6. Galizia G, Lieto E, Ferraraccio F, et al. Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 2004;10:3490-3499 (Pubitemid 38685457)
7. Edler D, Glimelius B, Hallstrom M, et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002;20:1721-1728 (Pubitemid 34273259)
8. Negri FV, Campanini N, Camisa R, et al. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer 2008;98:143-147
9. Font A, Abad A, Monzo M, et al. Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum 2001; 44:549-557 (Pubitemid 32336428)
10. Jernvall P, Makinen MJ, Karttunen TJ, Makela J, Vihko P. Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br J Cancer 1999;79:903-908 (Pubitemid 29082124)
11. Des Guetz GD, Uzzan B, Nicolas P, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006;94:1823-1832 (Pubitemid 43882572)
12. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611. (Pubitemid 39099316)
13. Kim JG, Chae YS, Sohn KS, et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 2008;14:62-66
14. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003;63:812-816 (Pubitemid 36231981)
15. Tsai WS, Changchien CR, Yeh CY, et al. Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer. Dis Colon Rectum 2006;49:883-894
16. De Vita F, Orditura M, Lieto E, et al. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 2004;100:270-278 (Pubitemid 38063634)
17. Karayiannakis AJ, Syrigos KN, Zbar A, et al. Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery 2007;131:548-555 (Pubitemid 34478504)
18. Kumar H, Heer K, Lee PW, et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998;4:1279-1285 (Pubitemid 28213341)
19. Zlobec I, Steele R, Compton CC. VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. Cancer 2005;104:2517-2521 (Pubitemid 41691576)
20. Chin KF, Greenman J, Gardiner E, Kumar H, Topping K, Monson J. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer 2000;83:1425-1431
21. Ogata Y, Matono K, Mizobe T, et al. The expression of vascular endothelial growth factor determines the efficacy of post-operative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Oncol Rep 2006; 15:1111-1116
22. Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007;57:168-185
23. Tamura M, Oda M, Tsunezuka Y, Matsumoto I, Kawakami K, Watanabe G. Vascular endothelial growth factor expression in metastatic pulmonary tumor from colorectal carcinoma: utility as a prognostic factor. J Thorac Cardiovasc Surg 2004;128: 517-522 (Pubitemid 39278384)
24. Bruns CJ, Liu WB, Davis DW, et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 2000;89:488-499
25. O'Dwyer PJ. The present and future of angiogenesis-directed treatments of colorectal cancer. Oncologist 2006;11:992-998 (Pubitemid 44564807)
26. Hoff P. Novel agents and targets for therapy of advanced colon cancer. Clin Adv Hematol Oncol 2007;5:365-366 (Pubitemid 47454907)
27. Logan-Collis JM, Lowy AM, Robinson-Smith TM, et al. VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol 2008;15:738-744
28. Roumen RM, Slooter GD, van Uchelen FA, Huib LV. Preoperative serum vascular endothelial growth factor is not a marker for subsequent recurrence during long-term follow-up of colorectal cancer patients. Dis Colon Rectum 2005;48: 1070-1075
29. Hyodo I, Doi T, Endo H, et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998;34:2041-2045 (Pubitemid 28546939)
30. Dirix LY, Vermeulen PB, Hubens G, et al. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 1996;7:843-848 (Pubitemid 26345876)
31. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998;152:1445-1452
32. Lee JK, Hong YJ, Han CJ, Hwang DY, Hong SI. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen? Int J Oncol 2000;17:149-152
33. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 2000;6: 3147-3152
34. Werther K, Christensen IJ, Nielsen HJ. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 2002;86:417-423 (Pubitemid 34185127)
35. Belizon A, Balik E, Horst P, et al. Persistent elevation of plasma vascular endothelial growth factor levels during the first month after minimally invasive colorectal resection. Surg Endosc 2008;22:287-297
36. Wu FP, Hoekman K, Sietses C, et al. Systemic and peritoneal angiogenic response after laparoscopic or convention colon resection in cancer patients: a perspective, randomized trial. Dis Colon Rectum 2004;47:1670-1674 (Pubitemid 39331980)
37. Gudehithlu KP, Ahmed N, Wu H, et al. Antagonism of vascular endothelial growth factor results in microvessel attrition and disorganization of wound tissue. J Lab Clin Med 2005; 145:194-203. (Pubitemid 40692402)
38. Yamaguchi T, Bando H, Mori T, et al. Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis. Cancer Science 2007;98:405-410 (Pubitemid 46195613)
39. Chin KF, Greenman J, Reusch P, Gardiner E, Marme D, Monson J. Changes in serum soluble VEGFR-1 and Tie-2 receptors in colorectal cancer patients following surgical resections. Anticancer Res 2004;24:2353-2358 (Pubitemid 39172191)